According to Cognyte Software's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.11215. At the end of 2022 the company had a P/E ratio of -2.10.
Year | P/E ratio | Change |
---|---|---|
2022 | -2.10 | -100.34% |
2021 | 610 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Abiomed ABMD | 64.8 | -1,160.17% | ๐บ๐ธ USA |
Intuitive Surgical ISRG | 86.3 | -1,511.24% | ๐บ๐ธ USA |
Cormedix CRMD | -6.30 | 3.11% | ๐บ๐ธ USA |
Nevro
NVRO | -4.31 | -29.52% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.